Clues to a Diagnosis: A Focus on Light-Chain Amyloidosis

Slides:

Advertisements

Similar presentations

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

State of the Art in BRCA-Mutated Ovarian Cancer

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

New Psoriasis Treatments

Applying Biosimilars in Hematologic Cancers

Improving Survival in Glioblastoma Multiforme

T-Cell Exhaustion: Can We Overcome It in Cancer?

Progression After Cancer Immunotherapy in Advanced NSCLC

Immune Reconstitution in MS:

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

Expert Perspectives on Best Practices for Diagnosis and Management of Spinal Muscular Atrophy.

New Standards of Care in ALK-Translocated Advanced NSCLC

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Nurse View.

Addressing Disease Burden in Asthma

Optimizing Management of Advanced Bladder Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Postpartum Depression

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Management of CMV in HSCT Recipients

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Ask the Experts.

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

CGRP Antibodies in Migraine

Optimizing Frontline Care for Older Patients With Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

New Data on Emerging Treatments for Psoriasis

Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.

Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Parkinson Disease Psychosis

Talking With Your Patients About Excessive Sweating

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient Questions and Expert Answers in Psoriasis:

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

The Psychiatrist's Role in Tardive Dyskinesia

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

New Clinical Insights Into the Pathology of Amyloidosis

Why New Treatments for Hyperhidrosis Should Be on Your Radar

The Psychiatrist's Role in Tardive Dyskinesia

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

Clues to a Diagnosis: A Focus on Light-Chain Amyloidosis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Differential Diagnosis of Monoclonal Gammopathies Mayo Clinic, Rochester, MN

Types of Amyloidosis Mayo Clinic, Rochester, MN, 2016

Light-Chain Amyloidosis

Biology of Amyloidosis

Nonspecific Symptoms

AL Amyloidosis Patient Experience Survey From ARC

AL Amyloidosis Patient Experience Survey From ARC (cont)

Organ Involvement in Patients With AL Amyloidosis

Key Signs of AL Amyloidosis

Case 1: 78-Year-Old Woman

Case 1: Biopsy Specimens From 78-Year-Old Woman

Case 2: 79-Year-Old Man

Case 3: Patient With Suspected Atypical MM

Case 3: BM Biopsy Congo Red X1000

Diagnostic Algorithm for Amyloidosis

Diagnostic Algorithm for Amyloidosis (cont)

Treatment Algorithm for AL Amyloidosis

Activity of Pomalidomide in Patients With AL

Potential Amyloid Active Agents

CPHPC Plus Anti-SAP mAb for Systemic Amyloidosis

First Compound for Diagnosis and Treatment of AL Amyloidosis: 11-1F4 mAb

NEOD001 Phase 1/2 Study: Expansion and Dose-Escalation

NEOD001 Phase 1/2 Study: Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)